French NASH and fibrosis disease biotech Inventiva is looking to build on its Big Pharma interest by filing for an IPO on the Euronext.

Novartis-backed gene therapy player GenSight is looking to bounce back from its failure to list on Nasdaq by pulling off a €40 million IPO in Paris.

Tesaro posted stellar Phase III results yesterday for its PARP inhibitor in ovarian cancer. But following on its good vibes have been other PARP R&D…

Syros Pharmaceuticals aims to use small molecules to control the activation and repression of genes. Now, it has raised $50 million in an IPO to get proof-of-…

Eleven Biotherapeutics, which has valiantly (or stubbornly) carried on over the past 12 months despite a slew of major trial failures, is now, finally, nearing…

On June 17, Neil Woodford upped his stake in Circassia. The next business day, Circassia posted Phase III trial data that caused its stock price to crash.

Sofinnova Partners' Antoine Papiernek not only agreed to co-lead the $33 million B round, he grabbed a seat on the board along with Nilesh Kumar from co-…

The struggling biotech Verastem that has seen its stock nose-dive will look to a future without executive chairman Christoph Westphal and director Henri…